期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

唑来膦酸规范化应用骨科专家研讨会纪要 被引量：2

原文传递
导出
摘要 2009年至今，越来越多的中国患者采用唑来膦酸（5mg）治疗骨质疏松。随着广泛的临床应用，虽然唑来膦酸（5mg）因其独特优势获得了临床医生的认可，但也出现一些普遍关注的具体问题，亟待沟通并解决。因此，骨科专家就唑来膦酸（5mg）在骨科临床应用中的使用经验，包括适用人群、使用时机及不良反应处理等问题进行深入交流与探讨，以指导广大骨科医生在实际工作中更加规范地使用。
出处 《中华骨科杂志》 CAS CSCD 北大核心 2013年第7期782-784,共3页 Chinese Journal of Orthopaedics
关键词 唑来膦酸 骨科专家 临床应用 2009年 骨质疏松 中国患者 临床医生 使用经验
分类号 R580 [医药卫生—内分泌]
  • 相关文献

参考文献19

  • 1原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. 被引量：1874
  • 2中华医学会骨科学分会.骨质疏松骨折珍疗指南.中华骨肿瘤骨病,2009,8(5): 287-291.
  • 3Reginster J, Minne HW, Sorensen OH, et al. Randomized trial ofthe effects of risedronate on vertebral fractures in women withestablished postmenopausal osteoporosis. Vertebral Efficacy withRisedronate Therapy (VERT) Study Group. Osteoporos Int, 2000,11(1): 83-91.
  • 4Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into ac-tions of bisphosphonates on bone: differences in interactions withhydroxy apatite. Bone, 2006, 38(5): 617-627.
  • 5Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and phar-macodynamics of zoledronic acid in cancer patients with bonemetastases. J Clin Pharmacol, 2002, 42(11): 1228-1236.
  • 6Black DM, Delmas PD, EastellR, et al. Once-yearly zoledronicacid for treatment of postmenopausal osteoporosis. N Engl J Med,2007,356(18): 1809-1822.
  • 7Lyles KW,Col6n-Emeric CS, Magaziner JS, et al. Zoledronic acidand clinical fractures and mortality after hip fracture. N Engl JMed, 2007, 357(18): 1799-1809.
  • 8Eriksen EF, Lyles KW, Colon-Emeric CS, et al. Antifracture effi-cacy and reduction of mortality in relation to timing of the firstdose of zoledronic acid after hip fracture. J Bone Miner Res,2009,24(7): 1308-1313.
  • 9Colon-Emeric C, Nordsletten L, Olson S, et al. Association be-tween timing of zoledronic acid infusion and hip fracture healing.Osteoporos Int, 2011,22(8): 2329-2336...
  • 10林华,徐天舒,范璐,杨海明,陈新,钱程.5mg唑来膦酸治疗绝经后骨质疏松及其骨折[J].中华创伤骨科杂志,2012,14(1):31-35. 被引量：34

二级参考文献24

  • 1郝永强,戴尅戎.骨质疏松性骨折愈合的细胞超微结构观察[J].中华骨科杂志,2004,24(11):670-673. 被引量：27
  • 2Buchbinder R,Osborne RH,Ebeling PR,et al.A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures.N Engl J Med,2009,361(6):557 -568.
  • 3Wardlaw D,Cummings SR,Van Meirhaeghe J,et al.Efficacy and safety of balloon kyphoplasty compared with non -surgical care for vertebral compression fracture (FREE):a randomised controlled trial.Lancet,2009,373(9668):1016-1024.
  • 4Singh AK,Pigram TK,Gilula LA.Osteoporotic compression fractures:outcomes after single-versus mulitiple-level percutaneous vertebroplasty.Radiology,2006,238(1):211 -220.
  • 5Taylor RS,Taylor RJ,Fritzell P.Balloon kyphoplasty and vertebroplasty for vertebral compression fractures:a comparative systematic review of efficacy and safety.Sipine,2006,31 (23):2747 -2755.
  • 6Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med,2007,356(18):1809-1822.
  • 7Hwang JS, Chin ES, Chen JF, et al. The effects of intravenous zoleclronie acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab, 2011, 29: 328-333.
  • 8Cauley JA, Black D, Boonen S, et al. Once-yearly zoledronic acid and days of disability, bed rest and back pain: randomised controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res, 2011, 26: 984-992.
  • 9Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and rise- dronate in the prevention and treatment of glucocorticoid-induced os- teoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, Lancet, 2009, 373: 1253-1263.
  • 10Reid DM. Update on the use of zoledronic acid in the management of osteoporosis. Curr Osteoporos Rep, 2010, 8: 145-150.

共引文献1914

同被引文献34

  • 1Alexandre C,Vico L. Pathophysiology of bone loss in disuse osteoporosis[J].{H}Joint Bone Spine:Revue du Rhumatisme,2011,(6):572-576.
  • 2Parker M,Johansen A. Hip fracture[J].{H}BMJ:British Medical Journal,2006,(7557):27-30.
  • 3Cotté FE,Fardellone P,Mercier F. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis[J].{H}Osteoporosis International,2010,(1):145-155.
  • 4Soong YK,Tsai KS,Huang HY. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan[J].{H}Osteoporosis International,2013,(2):511-521.
  • 5Eriksen EF,Lyles KW,Col6n-Emeric CS. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture[J].{H}Journal of Bone and Mineral Research,2009,(7):1308-1313.
  • 6Reid IR,Black DM,Eastell R. Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams[J].{H}Journal of Clinical Endocrinology and Metabolism,2013,(2):557-563.
  • 7Grey A,Bolland MJ,Horne A. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial[J].{H}BONE,2012,(6):1389-1393.
  • 8Boonen S,Orwoll E,Magaziner J. Once-yearly zoledronic acid in older men compared with women with recent hip fracture[J].{H}Journal of the American Geriatrics Society,2011,(11):2084-2090.
  • 9Kim TY,Ha YC,Kang BJ. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures[J].{H}JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME,2012,(7):956-960.
  • 10Col6n-Emeric C,Nordsletten L,Olson S. Association between timing of zoledronic acid infusion and hip fracture healing[J].{H}Osteoporosis International,2011,(8):2329-2336.

引证文献2

二级引证文献26

中华骨科杂志
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部